On the basis of the price per stock chart, we can see that the price has been reasonably consistent. So, while the price was $7.03 on May 10, 2021, it has now risen to $9.00. However, as compared to what it was on February 8, 2021, the present price is extremely low. $16.51 was the result. Will the present price level be the same as it was in February?
Anyone who follows the progress made at Sorrento Therapeutics (SRNE) will know that the company has an expanding pipeline covering a wide range of drugs, from cancer to lymphatic delivery systems. One part of the portfolio is dedicated to finding different solutions in the ongoing fight against Covid-19. Despite the pandemic’s retreat, analysts say investors should take into account “short-term value factors from Sorrento’s extensive portfolio of assets targeting complications caused by the COVID-19 infection.” One such asset is COVI-MSC.
The analyst notes that in a phase 1b trial focused on intensive care unit (ICU) circumstances, 100% of patients (n = 10) treated with COVI-MSC made a full recovery and were discharged from the hospital. As a result, SRNE has a ” Buy ” rating and a $30 target price for the company. When compared to current levels, the potential for development is as high as 254%.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.